{"title":"Osimertinib Plus Platinum-Pemetrexed: A Review in Previously Untreated, EGFR-Mutated, Locally Advanced or Metastatic NSCLC.","authors":"Amy Zhuang-Yan, Yahiya Y Syed","doi":"10.1007/s11523-026-01244-x","DOIUrl":null,"url":null,"abstract":"<p><p>Oral osimertinib (TAGRISSO<sup>®</sup>) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It is approved in several countries (including China, EU, Japan and the USA) for use in combination with platinum-pemetrexed chemotherapy as first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) (EU) or locally advanced or metastatic NSCLC (USA) whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations. In the pivotal phase III FLAURA2 trial in this patient population, osimertinib plus platinum-pemetrexed significantly prolonged median progression-free survival (PFS) and overall survival (OS) compared with osimertinib monotherapy. Osimertinib plus platinum-pemetrexed had a manageable tolerability profile, with safety consistent with that of the individual agents, and no new safety signals were identified. In conclusion, osimertinib plus platinum-pemetrexed is a valuable addition to the first-line treatment options for EGFR-mutated, locally advanced or metastatic NSCLC.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":"799-806"},"PeriodicalIF":5.1000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Targeted Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11523-026-01244-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Oral osimertinib (TAGRISSO®) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It is approved in several countries (including China, EU, Japan and the USA) for use in combination with platinum-pemetrexed chemotherapy as first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) (EU) or locally advanced or metastatic NSCLC (USA) whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations. In the pivotal phase III FLAURA2 trial in this patient population, osimertinib plus platinum-pemetrexed significantly prolonged median progression-free survival (PFS) and overall survival (OS) compared with osimertinib monotherapy. Osimertinib plus platinum-pemetrexed had a manageable tolerability profile, with safety consistent with that of the individual agents, and no new safety signals were identified. In conclusion, osimertinib plus platinum-pemetrexed is a valuable addition to the first-line treatment options for EGFR-mutated, locally advanced or metastatic NSCLC.
期刊介绍：
Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes:
Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches.
Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways.
Current Opinion articles that place interesting areas in perspective.
Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations.
Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement.
Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
